Related by context. All words. (Click for frequent words.) 56 AIM HIGH 55 ONTARGET 55 VADT 55 randomized clinical 53 multicentre randomized 53 randomized clinical trials 53 randomized controlled trial 52 randomized multicenter 52 HYVET 52 ALLHAT 52 observational study 52 substudy 52 randomized trials 52 multicenter randomized 52 randomized controlled 51 COURAGE 51 subanalysis 51 multicentre 51 prospective randomized 51 DCCT 51 Health Initiative WHI 51 ACCOMPLISH 51 multicenter 51 CARE HF 51 Phase III randomized 50 phase IIIb 50 MADIT II 50 ELCAP 50 WHI 50 placebo controlled clinical 50 randomized Phase III 50 SCD HeFT 50 ATTRACT 50 MADIT CRT 50 RE LY 49 placebo controlled randomized 49 EURIDIS 49 multicenter clinical 49 phase IIb 49 Randomized Evaluation 49 UKPDS 49 NCT# ClinicalTrials.gov 49 Phase Ib clinical 49 MADIT 49 prospective randomized controlled 49 candesartan 49 IMPROVE IT 49 RE LY ® 49 LUX Lung 49 prospective randomized placebo 49 statin therapy 48 multicenter randomized double 48 sunitinib 48 hypertensive patients 48 prospective cohort 48 randomized blinded 48 multicenter randomized controlled 48 MEND CABG 48 TMC# C# 48 ECASS 48 blind randomized 48 BCIRG 48 rosuvastatin 48 eptifibatide 48 placebo controlled Phase III 48 SIMPADICO 48 HPTN 48 multicentre prospective 48 GISSI HF 48 Aggressive Reduction 48 nonrandomized 48 COMPARE 48 NATRECOR R 48 double blinded randomized 48 clinical trial 47 ARBITER 6 47 ASTEROID 47 LITHE 47 randomized controlled trials 47 randomized placebo controlled 47 DAPT 47 telmisartan 47 ivabradine 47 ASCEND HF 47 double blinded placebo 47 ticagrelor 47 prospective multicenter 47 Phase 1a 47 ENDEAVOR IV 47 International Verapamil SR 47 Myocardial Infarction 47 PROactive study 47 POISE 47 REVIVE 47 CHD 46 Cardiovascular Risk 46 multicenter Phase II 46 DSMB 46 NO# [002] 46 NICE SUGAR 46 randomized controlled clinical trials 46 beta blocker therapy 46 SWOG 46 HeFT 46 CALGB 46 ATACAND 46 Carotid Revascularization Endarterectomy vs. 46 liver transplant recipients 46 WHEL 46 controlled multicenter 46 TRITON TIMI 46 CLL8 46 CHAMPION PCI 46 phase IIb clinical 46 ENDEAVOR 46 STRIDE PD 46 HOPE TOO 46 ACCLAIM 46 prospective multicentre 46 HIVNET 46 Prostate Cancer Prevention 46 cardiovascular mortality 46 EMPHASIS HF trial 46 multicenter prospective 46 Cholesterol Levels SPARCL 46 EVEREST II 46 randomized 46 iPrEx 46 multicentre randomized double 46 SYNTAX 46 antihypertensive medications 46 SPARCL 46 CAPRISA 46 Phase IIIb 46 valsartan 46 Intervention Trial 45 Intervention Effectiveness 45 GISSI 45 multicentre study 45 blinded randomized 45 prospective observational 45 Prostate Lung Colorectal 45 Randomized controlled 45 APPRAISE 45 ExTRACT TIMI 45 subgroup analyzes 45 EchoCRT 45 placebo controlled Phase 45 Phase 2b study 45 randomized controlled clinical 45 confirmatory clinical 45 AIR CF2 45 phase IIa 45 Percutaneous Coronary Intervention 45 microalbuminuria 45 Phase IIB 45 pertuzumab 45 tiotropium 45 CURRENT OASIS 7 45 placebo controlled 45 REGARDS 45 multicenter randomized clinical 45 Wisconsin Sleep Cohort 45 AVERROES 45 STICH 45 HF ACTION 45 placebo controlled studies 45 PLCO 45 landmark ATHENA 45 phase Ib 45 olmesartan 45 Telmisartan 45 NSTE ACS 45 trials RCTs 45 STICH trial 45 resistant hypertension 45 Hydroxyurea 45 PREVAIL 45 SPIRIT III 44 riociguat 44 BOLDER 44 multicenter study 44 label multicenter 44 acute coronary syndrome 44 EORTC 44 AVADO 44 BRIM3 44 BARI 2D 44 Evaluation WISE 44 stent thrombosis 44 Phase IIb trial 44 double blind placebo 44 blinded randomized controlled 44 Sorafenib HCC Assessment 44 CABANA 44 ORACLE MS 44 multicenter phase 44 systolic hypertension 44 clinical pharmacology studies 44 ENDEAVOR III 44 ASSERT 44 clazosentan 44 nonfatal MI 44 prospective randomized multicenter 44 PRoFESS 44 HORIZONS AMI trial 44 Cancer Prevention ATBC 44 Multicenter Automatic Defibrillator Implantation 44 Framingham Offspring Study 44 Acute Coronary Syndrome 44 multicenter Phase 44 Edge STudy 44 Clinical Antipsychotic Trials 44 glycemia 44 MADIT CRT trial 44 Trandolapril 44 TAXUS IV 44 INTERHEART study 44 BRIM2 44 macrovascular 44 multicenter placebo controlled 44 ILLUSTRATE 44 randomized crossover 44 noninferiority 44 STENT 44 Spine Patient Outcomes 44 ACRIN 44 antihypertensive therapy 44 macrovascular disease 44 randomized double 44 glucose lowering 44 APEX AMI trial 44 ENVISION 44 phase IIa clinical 44 Women Ischemia Syndrome 43 virologic failure 43 Ovarian Cancer Screening 43 TRIUMPH 43 proteinuria 43 HbA1c levels 43 COPERNICUS 43 randomized multicenter trial 43 PERSEUS 43 WOSCOPS 43 Dose escalation 43 ACUITY trial 43 homocysteine lowering 43 longitudinal cohort study 43 SPIRIT IV 43 multicentre randomized controlled 43 Stenting Trial CREST 43 CONQUER 43 randomized multicentre 43 MERLIN TIMI 43 NYHA functional class 43 SORT OUT 43 PFO migraine 43 non inferiority 43 Trial ASCOT 43 Phase III 43 randomized blinded placebo 43 adalimumab 43 randomized Phase IIb 43 ACCORD Lipid 43 label multicenter Phase 43 SWiTCH 43 Multi Ethnic Study 43 Sibutramine Cardiovascular Outcomes 43 fenretinide 43 Phase 1b trial 43 MIST II 43 UNLOAD 43 phase III ACCLAIM 43 Acute Myocardial Infarction 43 observational cohort 43 coronary revascularization 43 Aggressive Drug Evaluation 43 ALLEGRO 43 ENESTnd 43 PRE SURGE 43 phase IIb trial 43 CUSTOM II 43 CLARITY TIMI 43 nesiritide 43 Val HeFT 43 ACTIVE W 43 multicenter randomized placebo controlled 43 Phase 1b clinical 43 meta analyzes 43 ASCOT LLA 43 REALITY Trial 43 HbA 1c 43 sunitinib malate 43 prospective multicenter randomized 42 BOLDER II 42 afatinib 42 placebo controlled trials 42 Phase Ib 42 MOTIVATE 42 prospective nonrandomized 42 Phase 2b trial 42 TAXUS ATLAS 42 blind randomized placebo 42 Observational Study 42 Thrombolysis 42 AIR CF3 42 prospectively defined 42 ezetimibe simvastatin 42 ANCHOR trial 42 nondiabetic patients 42 PROACTIVE 42 HCV SPRINT 42 CABERNET 42 Digital Mammographic Imaging 42 hemoglobin A1c levels 42 Phase 2a trial 42 bevacizumab 42 Val MARC 42 Randomized 42 neoadjuvant 42 SPIRIT FIRST 42 CETP inhibition 42 UPLIFT 42 Clinical Outcomes Utilizing Revascularization 42 Intervention Trial GAIT 42 microvascular complications 42 normotensive 42 cardiovascular morbidity 42 bosentan 42 Communities ARIC study 42 warfarin therapy 42 HbA1c 42 Phase IIb clinical 42 lipid lowering therapy 42 Phase IIa 42 Phase III clinical 42 prespecified 42 WHIMS 42 unstable angina UA 42 SORT OUT III 42 ritonavir boosted 42 HCV RESPOND 2 42 Phase IIIb clinical 42 OLYMPIA registry 42 paricalcitol 42 thromboembolic events 42 NYHA Class II 42 observational studies 42 nab paclitaxel 42 TDF FTC 42 NT proBNP 42 RCTs 42 active comparator 42 prospectively randomized 42 Phase 2b 42 Phase III randomized controlled 42 Phase Ib II 42 periprocedural 42 Betaferon ® 42 selenium supplementation 42 Phase III trials 42 multicenter Phase III 42 plasma renin activity 42 APPRAISAL 42 triglyceride levels 41 meta analysis 41 Phase IIb 41 #:# randomization 41 iPrEx study 41 number NCT# ClinicalTrials.gov 41 CALGB # [001] 41 Lp PLA2 41 CRESTOR #mg 41 Lp PLA 2 41 Heart Failure Trial 41 LVSD 41 Platelet Inhibition 41 FOLPI 41 postmenopausal women 41 repeat revascularization 41 Cohort Study MACS 41 randomized controlled Phase 41 RIO Lipids 41 multicenter trials 41 placebo controlled dose escalation 41 NSABP B 41 doxorubicin docetaxel 41 AIDS Clinical Trials 41 secondary efficacy endpoints 41 pivotal bioequivalence 41 GRAVITAS trial 41 STELLAR 41 darunavir ritonavir 41 ADVANCE PD 41 Endovascular Valve Edge 41 CATIE 41 Atherosclerosis MESA 41 pharmacodynamic effects 41 pharmacodynamics 41 Multicenter 41 Phase IIa clinical 41 assessing T DM1 41 ABC/3TC 41 pharmacokinetics PK 41 elevated LDL cholesterol 41 eGFR 41 NATRECOR ® 41 APTIVUS 41 LDL C 41 blind multicenter 41 ToGA 41 post hoc 41 tipranavir 41 CHAMPION PLATFORM 41 MEDAL 41 Rosuvastatin 41 Prospective Randomized 41 PREVENT IV 41 randomized multicenter Phase III 41 ENDEAVOR II 41 atherogenic dyslipidemia 41 randomized Phase 41 #mg QD [002] 41 CYPHER Stent 41 oral ibandronate 41 eplerenone 41 heartwire 41 prospective longitudinal 41 cystatin C 41 ID NCT# 41 PRECISE 41 folate supplementation 41 myocardial infarctions 41 STEP BD 41 Phase IIa trial 41 blind randomized controlled 40 dose escalation Phase 40 stable angina 40 secondary endpoint 40 COPAXONE R 40 Acute Ischemic Stroke 40 PLCO trial 40 Phase 2a clinical 40 GOUT 40 LVEF 40 efficacy endpoint 40 TRANSFORMS 40 placebo controlled clinical trials 40 clopidogrel 40 RE LY trial 40 blinded placebo controlled 40 SABCS 40 Intervention Effectiveness CATIE 40 phase IIb study 40 serum triglycerides 40 Screening Trial DMIST 40 prospective observational studies 40 Phase 1b 40 dose titration 40 CYPHER ® Stent 40 Phase Ia 40 Hb A1C 40 factorial design 40 myocardial infarction MI 40 chemoradiotherapy 40 subclinical hypothyroidism 40 thorough QT 40 COPD 40 hypertensive 40 PROBE 40 Chronic Heart Failure 40 dexpramipexole 40 Multicentre 40 antihypertensive agents 40 dose escalation trial 40 Phase 2b kidney transplant 40 T2DM 40 cluster randomized controlled 40 DU #b 40 prospective multicenter study 40 Gynecologic Oncology Group 40 calcium supplementation 40 CAVEATS 40 Anticoagulation 40 virologic response 40 ENGAGE AF TIMI 40 ARIXTRA 40 ACCELERATE 40 PROCRIT therapy 40 Atherosclerosis Risk 40 KRN# 40 Cardiac Allograft Rejection 40 MiDAS 40 lipid lowering drugs 40 KIF6 carriers 40 NCCTG 40 STEMI patients 40 Subgroup analysis 40 RTOG 40 baseline HbA1c 40 dose escalation phase 40 Multicenter AIDS 40 Study ADCS 40 multicenter multinational 40 Meta analyzes 40 Phase III metastatic melanoma 40 PARTNER 40 diastolic heart 40 Alpha Tocopherol Beta Carotene 40 Phase #/#a 40 composite endpoint 40 postmenopausal 40 Multiethnic Study 40 preserved ejection fraction 40 Phase III placebo controlled 40 REVIVE Diabetes 40 dose atorvastatin 40 premenopausal women 40 Phase III VISTA 40 coinfected patients 40 rFVIIa 40 lowering LDL cholesterol 40 dietary modification 40 hemoglobin A1c HbA1c 40 CrCl 39 Stenting Trial 39 polyarticular 39 recurrent ischemia 39 Left Ventricular Dysfunction 39 reinfarction 39 antioxidant supplementation 39 masked placebo controlled 39 cardiac dysfunction 39 randomized controlled trials RCTs 39 ADAGIO study 39 statistically significant differences 39 Complications Trial 39 left ventricular dysfunction 39 periprocedural MI 39 clinical trials 39 Subgroup analyzes 39 Phase IIA 39 pharmacokinetic pharmacodynamic 39 CHARM 39 Stop Hypertension DASH diet 39 single ascending dose 39 antiretroviral naïve 39 nulliparous women 39 patients undergoing percutaneous 39 letrozole 39 cardiovascular hospitalizations 39 Randomized trials 39 A1c levels 39 fosbretabulin 39 dietary questionnaires 39 blind multicentre 39 dabigatran etexilate 39 ACOSOG Z# 39 NYHA class 39 vicriviroc 39 systolic dysfunction 39 AREDS 39 POAG 39 ACTEMRA 39 Ovarian PLCO Cancer 39 Prospective Randomized Trial 39 longitudinal studies 39 anti arrhythmic drug 39 IMPACT DCM clinical 39 bendamustine 39 hypertension 39 Phase 1a clinical 39 CARDIA 39 dosage regimens 39 FOSRENOL R 39 Screening Trial 39 CLARITY study 39 TAXUS VI 39 coronary heart 39 CABG 39 AIR CF1 39 endothelial dysfunction 39 dose statin therapy 39 dose escalation 39 serum GGT 39 HAART regimens 39 perinatal mortality 39 hypercholesterolemic patients 39 Communities ARIC Study 39 systolic blood pressure 39 Metabolic Efficiency 39 ABCSG 39 cardiovascular hospitalization 39 retrospective observational study 39 teriflunomide 39 peg interferon 39 ascending doses 39 dose escalation study 39 Trial PCPT 39 RELIANT 39 impaired fasting glucose 39 monotherapy 39 left ventricular hypertrophy 39 Radiation Therapy Oncology 39 registrational Phase 39 β blockers 39 PRADAXA 39 glycosylated hemoglobin 39 Coronary Heart Disease 39 onset atrial fibrillation 39 ximelagatran 39 prospective observational cohort 39 acute coronary syndromes 39 hypertensives 39 relapsing multiple sclerosis 39 PRECiSE 39 pre menopausal 39 tolerability 39 lacosamide 39 blinded randomized placebo controlled 39 ENDEAVOR clinical 39 MDRD 39 label multicenter randomized 39 TMC# r 39 onset AF 39 fasting glucose levels 39 OUTCOMES 39 retrospective cohort 39 SPRINT 39 myocardial infarctions MIs 39 severe sepsis 39 NCCTG N# 39 cerebrovascular events 39 VT VF 39 RESOLUTE clinical 39 NHANES III 39 Myocardial Infarction Study 39 Hypertension 39 ADHF 39 enroller 39 pre eclampsia 39 carotid IMT 39 dyslipidaemia 39 atherothrombotic disease 39 echocardiographic 39 Fonarow 38 retrospective cohort study 38 myocardial infarction stroke 38 dosing cohorts 38 noncardiac surgery 38 noninferior 38 sudden cardiac death 38 BEACOPP 38 Randomized Clinical Trial 38 non valvular atrial 38 thromboembolic 38 ADMIRE HF 38 sirolimus eluting stents 38 BR.# study 38 Cochrane Systematic Review 38 multivitamin supplementation 38 nonfatal stroke 38 Acute Decompensated Heart Failure 38 ascending dose 38 RoACTEMRA 38 dose dose escalation 38 AZILECT R 38 LEXIVA r 38 serum phosphate 38 recurrent glioblastoma multiforme 38 clopidogrel pretreatment 38 ARDIS 38 modifiable risk 38 CAMMS# 38 canakinumab 38 GASTRIC 38 TROPIC 38 thrombotic events 38 QD dosing 38 unblinded 38 antithrombotic therapy 38 VITAL Trial 38 Acute Coronary Syndromes ACS 38 systolic BP 38 randomisation 38 atherothrombotic 38 subclinical atherosclerosis 38 atherothrombosis 38 pharmacokinetic characteristics 38 COMFORT II 38 pharmacokinetic PK 38 microvascular disease 38 carotid atherosclerosis 38 multiple ascending dose 38 prostate cancer CaP 38 asymptomatic carotid stenosis 38 serum uric acid 38 desvenlafaxine succinate 38 designated HVTN 38 CORD II 38 T2D 38 bronchial thermoplasty 38 mg BID dose 38 ACTEMRA TM 38 XIENCE V demonstrated 38 Primary endpoints 38 ipsilateral stroke 38 lipid levels 38 hypercholesterolemia 38 hsCRP 38 MetS 38 ASSURE 38 PATENT 38 Dialysis Outcomes 38 coronary disease 38 antiplatelet therapy 38 ORMD 38 bevacizumab Avastin 38 intensive statin therapy 38 macroalbuminuria 38 Raloxifene Evaluation MORE 38 genomewide association study 38 Nord Trøndelag Health 38 AIR2 Trial 38 COGENT 38 Abciximab 38 dose escalation clinical 38 fasting serum 38 Randomised 38 randomized #:# 38 Randomized Study 38 hyperglycaemia 38 boosted protease inhibitor 38 ENABLE 38 Acute myocardial infarction 38 adiponectin concentrations 38 vitamin D supplementation 38 Combination therapy 38 fasting glucose 38 Group RTOG 38 dose regimen 38 Ranolazine 38 Torisel 38 serum creatinine levels 38 Sudden Cardiac Death 38 PREZISTA r 38 atherosclerotic renal artery stenosis 38 pCR 38 RSD# oral 38 STEMI 38 PRECEDENT 38 ConclusionThis 38 stratifying patients 38 Patency 38 antiretroviral naive 38 symptomatic BPH 38 thrombolytic therapy 38 landmark ATHENA trial 38 CAPACITY 38 glatiramer acetate 38 Phase 2b clinical 38 dosing regimens 38 study1 37 atazanavir ritonavir 37 cortical stimulation 37 MIST 37 longitudinal observational study 37 left ventricular ejection 37 PHPT 37 symptomatic VTE 37 T1DM 37 oral deforolimus 37 coronary intervention 37 LV dysfunction 37 REVLIMID lenalidomide 37 serum lipid levels 37 patientswith 37 Epidemiologic studies 37 blind placebo controlled 37 HbA1C levels 37 Polyp Prevention Trial 37 Diabetes Mellitus 37 atherosclerotic progression 37 Young Adults CARDIA 37 Phase III randomized placebo 37 BENICAR HCT 37 dyskinesia PD LID 37 Swedish Mammography Cohort 37 cardiovascular disease 37 NOMID 37 dose regimens 37 statistically nonsignificant 37 oral FTY# 37 pegylated interferon alfa 2b 37 viral kinetic 37 TQT 37 glycated hemoglobin levels 37 dietary patterns 37 coronary artery disease 37 secondary efficacy endpoint 37 nonvertebral fractures 37 II Clinical Trial 37 Observational studies 37 serum IGF 37 TURNS Treatment 37 Prospective Multicenter 37 blind placebo 37 ischemic heart 37 XIENCE V Stent System 37 cinacalcet 37 clinically meaningful 37 cilostazol 37 longitudinal study 37 lipid parameters 37 Controlled Trial 37 oral PrEP 37 unblinding 37 eprotirome 37 albuminuria 37 prehypertension 37 viral kinetics 37 inhibitor RG# 37 HCV infected 37 Rosiglitazone Evaluated 37 reboxetine 37 atrial fibrillation AF 37 preterm infants 37 tHcy 37 Enzastaurin 37 recurrent prostate cancer 37 Intervention Trial Evaluating 37 CIMZIA TM certolizumab pegol 37 paclitaxel eluting stents 37 TRUST 37 Sipuleucel T 37 LCP AtorFen 37 cerebral microbleeds 37 Phase III pivotal 37 ZACTIMA 37 DMIST 37 epidemiologic studies 37 Kaplan Meier analysis 37 treatment naive genotype 37 ischemic stroke 37 peginterferon alfa 2b 37 Current Controlled Trials 37 RE MODEL 37 Placebo controlled 37 severe hypoglycemia 37 HbA1C 37 CUSTOM III 37 gallstone disease 37 pivotal Phase III 37 venous thromboembolic events 37 Sequenced Treatment Alternatives 37 serum triglyceride levels 37 diabetes mellitus 37 neoadjuvant treatment 37 label dose escalation 37 EARNEST 37 TOHP 37 Decompensated Heart Failure 37 pharmacodynamic profile 37 Prehypertension 37 rimonabant #mg 37 recurrent VTE 37 fatal myocardial infarction 37 Framingham Offspring 37 atherosclerosis 37 dysglycemia 37 safety tolerability pharmacokinetics 37 extrapyramidal symptoms 37 AA Amyloidosis 37 GELA 37 platelet reactivity 37 rosuvastatin Crestor 37 relapsed MM 37 aldosterone antagonists 37 Lipid Lowering Treatment 37 sorafenib Nexavar 37 COMPANION 37 cardiovascular disease CVD 37 cerebral vasospasm 37 everolimus eluting stents 37 hemodilution 37 prognostic significance 37 postoperative mortality 37 Xelox 37 placebo 37 Drug Eluting Stent System 37 Glucosamine Chondroitin Arthritis 36 mg administered orally 36 LQTS 36 CLA supplementation 36 IMPROVE HF 36 thromboprophylaxis 36 serum calcium levels 36 testosterone supplementation 36 recurrent malignant glioma 36 #mg dose [003] 36 STRIDE 36 SCOUT 36 morphometric vertebral fractures 36 multivariate Cox 36 deferiprone 36 pegylated liposomal doxorubicin 36 CAPRA 36 serum leptin 36 flibanserin #mg 36 adjuvant chemotherapy 36 nondiabetics 36 PICSO ® 36 ibandronate 36 spontaneous preterm delivery 36 OGTT 36 study 36 solifenacin 36 elevated triglycerides 36 multivariable analysis 36 label dose titration 36 Endarterectomy 36 Normative Aging Study 36 estrogen progestin therapy 36 claudication 36 Dabigatran 36 epidemiological studies 36 zotarolimus eluting stent 36 perinatal outcomes 36 HIV HCV coinfected 36 lipid profiles 36 Phase Ib study 36 oral rivaroxaban 36 CLBP 36 APTIVUS r 36 atherosclerotic disease 36 EDICT 36 Oxidized LDL 36 Elocalcitol 36 nonfasting triglyceride levels 36 familial AF 36 Baseline characteristics 36 plus ribavirin 36 epithelial ovarian cancer 36 mm Hg systolic 36 AST ALT 36 LPV r 36 pharmacodynamics PD 36 Randomized Controlled Trial 36 prostate cancer PCa 36 plasma folate 36 REVERSE 36 serum vitamin D 36 carotid endarterectomy CEA 36 intima media thickness 36 metabolic parameters 36 disease CHD 36 undergoing CABG 36 RECOVER 36 carotid intima media 36 optimal dosing 36 definite stent thrombosis 36 OLE 36 unstable angina pectoris 36 Phase IIIb study 36 PREPARATORY 36 Surgical Treatment 36 fasting triglyceride levels 36 LDL cholesterol levels 36 #mg/day [001] 36 MOSAIC 36 RECORD1 36 mycophenolate mofetil 36 teriparatide 36 coronary blockages 36 asymptomatic PAD 36 ketogenic diet 36 rt PA 36 CVD mortality 36 antiepileptic drug 36 Longitudinal studies 36 efficacy tolerability 36 serum concentrations 36 pharmacokinetic interaction 36 arterial hypertension 36 lipoprotein 36 BR.# 36 DAPT Study 36 vertebral fractures 36 risperidone Risperdal 36 donepezil 36 RG# ITMN 36 C reactive protein 36 endothelin antagonists 36 adenoma recurrence 36 Multivariate analysis 36 prostate carcinogenesis 36 eculizumab therapy 36 Stent thrombosis 36 acute coronary